CUSTOMS Notification No 16 of 2017 dt 20th April, 2017

 

 

Notification no 16/2017 Customs date on 20th April, 2017

 

 

The extract of CUSTOMS Notification No. 16/2017- CUSTOMS is given below:

 

Notification No. 16/2017-CUSTOMS

 

[TO BE PUBLISHED IN PART II, SECTION 3, SUB-SECTION (i) OF THE GAZETTE OF INDIA, EXTRAORDINARY]

 

GOVERNMENT OF INDIA

MINISTRY OF FINANCE

(Department of Revenue)

 

Notification No. 16 /2017-Customs

 

New Delhi, the 20th April, 2017

 

G.S.R.           (E).- In exercise of the powers conferred by sub-section (1) of section 25 of                 the

 

Customs Act, 1962 (52 of 1962), the Central Government, being satisfied that it is necessary in the public interest so to do, hereby exempts the goods, falling under Chapter 30 of the First Schedule to the Customs Tariff Act, 1975 (51 of 1975), of the description specified in column (2) of the Table below, for supply under Patient Assistance Programmes specified in the corresponding entry in column (3) of the said Table, run by the pharmaceutical companies specified in the corresponding entry in column (4) of the said Table, when imported into India, from the whole of the duty of customs leviable thereon which is specified in the First Schedule to the said Customs Tariff Act, subject to the following conditions, namely:-

 

(a)    the drugs and medicines are supplied free of cost to the patients under the Patient Assistance Programme of the specified pharmaceutical company;

 

(b)   the said pharmaceutical company furnishes an undertaking to the Assistant Commissioner of Customs or the Deputy Commissioner of Customs, as the case may be, having jurisdiction, to the effect that-

 

(i)             it shall maintain the following records:-

 

(A)      name, age, gender, residence and contact details of the patient;

 

(B)       copies of valid identity proof and residence proof of the patient and the caregiver, if any, as the case may be;

 

(C)      the disease diagnosed and the prescribed dosage of drugs and medicines;

 

(D)      the drugs and medicines imported or received and consumed under the said programme;

 

(ii)              the goods shall be used for the specified purpose only;

 

(c)    The said pharmaceutical company also furnishes an undertaking to the Assistant Commissioner of Customs or Deputy Commissioner of Customs, as the case may be, having jurisdiction, to pay, in the event of failure to comply with any of the aforesaid conditions, an amount equal to the duty leviable on such goods but for the exemption contained in this notification, along with the applicable interest thereon.

 

TABLE

 

Sr.

Description of drug /

 

Name of Patient

Name of pharmaceutical

 

No.

medicine

Assistance Programme

company running Patient

 

 

 

 

 

 

 

 

Assistance Programme

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

 

(2)

 

 

(3)

 

 

 

 

(4)

 

 

 

 

 

 

 

 

 

1.

Xtandi (Enzulatamide)

Xtandi

 

Patient

Astellas Pharma India Pvt. Ltd.

 

 

 

Assistance Programme

 

 

 

 

 

 

 

 

 

 

 

 

2.

Dasatinib (Sprycel)

Sprycel

 

Assistance

Bristol Myers Squibb India Pvt.

 

 

 

Program

 

 

 

Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

3.

Nivolumab (Opdyta)

OASIS

 

 

 

Bristol Myers Squibb India Pvt.

 

 

 

 

 

 

 

 

Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.

Halaven

(Eribulin

Hope to Her –

 

 

Eisai

Pharmaceuticals

India

Pvt.

 

medylate)

-   Metastatic

2 to 3 cycles purchased

Ltd.

 

 

 

 

 

 

Breast cancer, Soft Tissue

and

balanced

free

upto

 

 

 

 

 

 

 

Sarcoma

 

disease progression

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HELP -

 

 

 

Eisai

Pharmaceuticals

India

Pvt.

 

 

 

All cycles free for below

Ltd.

 

 

 

 

 

 

 

 

poverty line patients

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5.

Zonegran

(Zonisamide)  -

Livefree - 33%

 

Eisai

Pharmaceuticals

India

Pvt.

 

for Epilespy

Support  to  patients

for

Ltd.

 

 

 

 

 

 

 

 

extending

duration

of

 

 

 

 

 

 

 

 

 

treatment  as  this  is  a

 

 

 

 

 

 

 

 

 

chronic therapy

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6.

Imbruvica

 

1+1 PAP

 

 

 

Janssen

India,

Johnson

&

 

 

 

 

 

 

 

 

Johnson Pvt. Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7.

Zytiga

 

3+1 PAP

 

 

 

Janssen

India,

Johnson

&

 

 

 

 

 

 

 

 

Johnson Pvt. Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

8.

Velcade 1mg

3+1 PAP

 

 

 

Janssen

India,

Johnson

&

 

 

 

 

 

 

 

 

Johnson Pvt. Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

9.

Velcade 3.5 mg

1+1 PAP

 

 

 

Janssen

India,

Johnson

&

 

 

 

 

 

 

 

 

Johnson Pvt. Ltd.

 

 

 

10.

Caelax

 

1+1 PAP

 

 

 

Janssen

India,

Johnson

&

 

 

 

 

 

 

 

 

Johnson Pvt. Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11.

Dacogen

 

1+1 PAP

 

 

 

Janssen

India,

Johnson

&

 

 

 

 

 

 

 

 

Johnson Pvt. Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

12.

Yondelis

 

1+1 PAP

 

 

 

Janssen

India,

Johnson

&

 

 

 

 

 

 

 

 

Johnson Pvt. Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

13.

Simponi

 

1

vial

free

on

1st

Janssen

India,

Johnson

&

 

 

Sr.

Description of drug /

Name of Patient

 

Name of pharmaceutical

 

No.

medicine

Assistance Programme

company running Patient

 

 

 

 

 

 

 

Assistance Programme

 

 

 

 

 

 

 

 

 

 

 

(1)

(2)

 

 

(3)

 

 

(4)

 

 

 

 

 

 

 

 

 

 

 

 

purchase

 

 

Johnson Pvt. Ltd.

 

 

 

 

 

 

 

 

 

14.

Remicade

5+4  on  3  dose  therapy,

Janssen

India,

Johnson

&

 

 

6+6 on 4 dose therapy

 

Johnson Pvt. Ltd.

 

 

 

 

 

 

 

 

 

 

15.

Invega all SKUs

1+1  PAP

(Maintenance

Janssen

India,

Johnson

&

 

 

dosage)

 

 

Johnson Pvt. Ltd.

 

 

 

 

 

 

 

 

 

16.

Imatinib (Glivec)

Glivec

NOA  Program/

Novartis India Ltd.

 

 

 

 

Glivec International PAP

 

 

 

 

 

 

 

 

 

 

17.

Nilotinib (Tasigna)

Win for Patients - Cancer

Novartis India Ltd.

 

 

 

 

Care

 

 

 

 

 

 

 

 

 

 

 

 

 

18.

Ruxolitinib (Jakavi)

Win for Patients - Cancer

Novartis India Ltd.

 

 

 

 

Care

 

 

 

 

 

 

 

 

 

 

 

 

 

19.

Everolimus (Afinitor)

Win for Patients - Cancer

Novartis India Ltd.

 

 

 

 

Care

 

 

 

 

 

 

 

 

 

 

 

 

 

20.

Ceritinib (Spexib)

Win for Patients - Cancer

Novartis India Ltd.

 

 

 

 

Care

 

 

 

 

 

 

 

 

 

 

 

 

 

21.

Pazopanib (Votrient)

Win for Patients - Cancer

Novartis India Ltd.

 

 

 

 

Care

 

 

 

 

 

 

 

 

 

 

 

 

 

22.

Eltrombopag (Revolade)

Win for Patients - Cancer

Novartis India Ltd.

 

 

 

 

Care

 

 

 

 

 

 

 

 

 

 

 

 

 

23.

Indicaterol (Sequadra)

Win for Patients - COPD

Novartis India Ltd.

 

 

 

 

 

 

 

 

 

 

 

24.

Secukinumab (Scapho)

Win

for

Patients

-

Novartis India Ltd.

 

 

 

 

Skincare

 

 

 

 

 

 

 

 

 

 

 

 

25.

Omalizumab (Xolair CSU)

Win for Patients – Skin

Novartis India Ltd.

 

 

 

 

care

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

26.

Ranibizumab (Accentrix)

Win

for

Patients

-

Novartis India Ltd.

 

 

 

 

Visioncare

 

 

 

 

 

 

 

 

 

 

 

 

27.

RITUXIMAB

SPARSH - The Touch

 

Dr. Reddy's Laboratories Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

[F.No.332/24/2010-TRU (Pt.I)]

 

 

 

 

(Mohit Tewari)

Under Secretary to the Government of India


Discussion Forum

You can also share your thoughts about this article.
Any one can answer on question posted by Readers